Overview:
With the development of antibody-drug conjugates and immune checkpoint inhibitors, the treatment of both adult and pediatric patients with advanced Hodgkin lymphoma (HL) is undergoing a transformation. New therapeutic targets are also emerging for patients with relapsed/refractory disease. Thus, there is a need for education regarding current and emerging novel therapeutic approaches in the management of HL.
This How We Do It® live webcast will bring together clinical experts in lymphoma to highlight evolving approaches to the diagnosis and treatment of patients with HL. Evidence-based assessments of current standards of practice and the most important clinical trials will set the stage for extensive case-based discussion sessions, which will address newly diagnosed patients, relapsed/refractory disease, and pediatric patients. Additionally, strategies to maximize the safety of treatment regimens in patients with HL will be evaluated.
Learning Objectives:
Upon completion of this activity, participants will be able to:
- Develop personalized care plans for patients with HL based on patient-related factors, risk stratification and treatment history
- Explain the efficacy and safety of evolving adult and pediatric strategies for advanced HL from clinical trials, including real world evidence in multiple lines of care
- Apply proactive strategies to recognize and manage adverse events associated with the use of novel therapies for the management of adult and pediatric patients with advanced HL
- Utilize evidence to develop case-based strategies for the management of adult and pediatric patients with HL
Target Audience: This educational activity is directed toward medical oncologists, hematologic oncologists, hematologists, oncology nurses and other healthcare professionals involved in the treatment of Hodgkin lymphoma.
| Time (ET) | Topic | Length | |
| 7:00 AM | Welcome and Introductions | Joseph M. Connors, MD, CM | 0:05 |
| 7:05 AM | Frontline Approaches for Hodgkin Lymphoma | Joseph M. Connors, MD, CM | 0:25 |
| 7:30 AM | Managing Relapsed/Refractory Hodgkin Lymphoma | Craig H. Moskowitz, MD | 0:25 |
| 7:55 AM | How We Do It: How We Treat Adult Hodgkin Lymphoma in the Frontline Setting | Joseph M. Connors, MD, CM Craig H. Moskowitz, MD |
0:30 |
| 8:25 AM | Overview of Hodgkin’s Lymphoma in Pediatric Patients | Paul Harker-Murray, MD | 0:20 |
| 8:45 AM | How We Do It: How We Treat Pediatric Patients with Hodgkin Lymphoma | Paul Harker-Murray, MD | 0:10 |
| 8:55 AM | Postsession survey | 0:05 | |
| 9:00 AM | Adjourn |
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.
Joseph M. Connors, MD, CM
Professor Emeritus
BC Cancer Centre for Lymphoid Cancer
Department of Medicine
University of British Columbia
Vancouver, BC, Canada
Craig H. Moskowitz, MD
Physician-in-Chief, Oncology Service Line
Sylvester Comprehensive Cancer Center
Professor of Medicine, Division of Hematology
University of Miami Health System
Miami, FL
Paul Harker-Murray, MD
Professor at Medical College of Wisconsin
Milwaukee, WI
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.